Involvement of cytochrome P450 1A2 in the biotransformation of trans-resveratrol in human liver microsomes

被引:122
作者
Piver, B
Fer, M
Vitrac, X
Merillon, JM
Dreano, Y
Berthou, F
Lucas, D
机构
[1] Biochem Lab, Fac Med, EA 948, F-29238 Brest, France
[2] Univ Bordeaux 2, Lab Mycol & Biotechnol Vegetale, EA 941, F-33076 Bordeaux, France
关键词
trans-resveratrol; piceatannol; cytochrome p450; CYP1A1; CYP1A2; CYP1B1;
D O I
10.1016/j.bcp.2004.05.008
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
This study was aimed at identifying the isoform(s) of human liver cytochrome P450 (CYP) involved in the hepatic biotransformation of trans-resveratrol (trans-3,5,4'-trihydroxystilbene). Trans-resveratrol metabolism was found to yield two major metabolites, piceatannol (3,5,3',4'-tetrahydroxystilbene) and another tetrahydroxystilbene named M1. Trans-resveratrol was hydroxylated to give piceatannol and M1 with apparent K-m of 21 and 31 muM, respectively. Metabolic rates were in the range 14-101 pmol min(-1) mg(-1) protein for piceatannol and 29-161 pmol min(-1) mg(-1) protein for M1 in the 13 human liver microsomes tested. Using microsomal preparations from different human liver samples, piceatannol and M1 formation significantly correlated with ethoxy-resorufin-O-deethylation (r(2) = 0.84 and 0.88, respectively), phenacetin-O-deethylation (r(2) = 0.92 and 0.94) and immuno-quantified CYP1A2 (r(2) = 0.85 and 0.90). Formation of these metabolites was markedly inhibited by alpha-naphthoflavone and furafylline, two inhibitors of CYP1A2. Antibodies raised against CYP1A2 also inhibited the biotransformation of trans-resveratrol. In addition, the metabolism of trans-resveratrol into these two metabolites was catalyzed by recombinant human CYP1A1, CYP1A2 and CYP1B1. Our results provide evidence that in human liver, CYP1A2 plays a major role in the metabolism of trans-resveratrol into piceatannol and tetrahydroxystilbene M1. (C) 2004 Elsevier Inc. All rights reserved.
引用
收藏
页码:773 / 782
页数:10
相关论文
共 32 条
[1]  
Andlauer W, 2000, DRUG EXP CLIN RES, V26, P47
[2]  
Bertelli AAE, 1996, INT J CLIN PHARM RES, V16, P77
[3]  
BERTHOU F, 1991, DRUG METAB DISPOS, V19, P561
[4]  
BURKE MD, 1985, BIOCHEM PHARMACOL, V34, P33
[5]   Resveratrol, a red wine constituent, is a mechanism-based inactivator of cytochrome P450 3A4 [J].
Chan, WK ;
Delucchi, AB .
LIFE SCIENCES, 2000, 67 (25) :3103-3112
[6]   Trans-resveratrol modulates the catalytic activity and mRNA expression of the procarcinogen-activating human cytochrome P4501B1 [J].
Chang, TKH ;
Lee, WBK ;
Ko, HH .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2000, 78 (11) :874-881
[7]   Real-time polymerase chain reaction analysis of CYP1B1 gene expression in human liver [J].
Chang, TKH ;
Chen, J ;
Pillay, V ;
Ho, JY ;
Bandiera, SM .
TOXICOLOGICAL SCIENCES, 2003, 71 (01) :11-19
[8]   Effect of trans-resveratrol on 7-benzyloxy-4-trifluoromethylcoumarin O-dealkylation catalyzed by human recombinant CYP3A4 and CYP3A5 [J].
Chang, TKH ;
Yeung, RKY .
CANADIAN JOURNAL OF PHYSIOLOGY AND PHARMACOLOGY, 2001, 79 (03) :220-226
[9]  
Chang TKH, 2001, J PHARMACOL EXP THER, V299, P874
[10]   Resveratrol is a selective human cytochrome P450 1A1 inhibitor [J].
Chun, YJ ;
Kim, MY ;
Guengerich, FP .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1999, 262 (01) :20-24